Publications by authors named "M Trbusek"
Background: Telomeres are protective structures at chromosome ends which shorten gradually with increasing age. In chronic lymphocytic leukemia (CLL), short telomeres have been associated with unfavorable disease outcome, but the link between clonal evolution and telomere shortening remains unresolved.
Methods: We investigated relative telomere length (RTL) in a well-characterized cohort of 198 CLL patients by qPCR and focused in detail on a subgroup 26 patients who underwent clonal evolution of TP53 mutations (evolTP53).
Article Synopsis
- The study investigates the effects of rituximab on chronic lymphocytic leukemia (CLL) patients, focusing on how individual variations influence CLL cell count reduction shortly after treatment.
- Findings indicate that better CLL cell elimination is linked to lower initial cell counts, higher CD20 expression, and a robust complement-dependent cytotoxicity response.
- It was observed that although CLL cell counts can significantly drop initially, many patients experienced a rebound effect, leading to higher CLL cell counts 24 hours post-treatment, which is associated with CDC exhaustion and changes in immune cell interactions.
ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
Cancer Treat Rev
August 2020
Progress in cancer therapy changed the outcome of many patients and moved therapy from chemotherapy agents to targeted drugs. Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), ibrutinib (Bruton's tyrosine kinase inhibitor) in chronic lymphocytic leukemia (CLL), venetoclax (BCL2 inhibitor) in CLL and acute myeloid leukemia (AML) or midostaurin (FLT3 inhibitor) in AML. In this review, we focused on DNA damage response (DDR) inhibition, specifically on inhibition of ATR-CHK1 pathway.
View Article and Find Full Text PDFBackground: Signal transducer and activator of transcription (STAT) proteins are cytoplasmic transcription factors that transmit the signal of cytokines, hormones and growth factors. STAT proteins control fundamental cellular processes including survival, proliferation and differentiation. Inappropriate activation of STATs might contribute to cellular transformation and leukaemogenesis.
View Article and Find Full Text PDFTP53 gene defects represent the most unfavorable prognostic factor in chronic lymphocytic leukemia (CLL). Although recently introduced small-molecule B-cell receptor signalling inhibitors have revolutionized CLL treatment, data for ibrutinib still point to impaired prognosis for TP53-affected patients. Among cancer-associated TP53 mutations, missense substitutions predominate and typically result in a high mutated-p53 protein level.
View Article and Find Full Text PDF